What is Neurogene's market cap?

Neurogene (NGNE) has a market capitalization of $690.7M and trades on NASDAQ.

Who are Neurogene's competitors?

Neurogene's key competitors include Ultragenyx Pharmaceutical, Passage Bio, Inc. Common Stock, Taysha Gene Therapies, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Neurogene partner with?

Neurogene's notable partners include University of Edinburgh.

Where is Neurogene headquartered?

Neurogene is headquartered in United States of America and employs approximately 91 people. It has been publicly traded since 2023.

Neurogene

NGNE

Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for rare and devastating neurological diseases.

Market cap

$690.68M+121%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

EPS-$1.39Miss by $0.09

Read the full report

Next report

Aug 10, 2026 (In 1 week)

EPS estimate-$1.40

Competitors

By market cap

Ultragenyx Pharmaceutical$2.6B+1.5%

GeneDx Holdings$1.8B-25.8%

Taysha Gene Therapies, Inc.$1.6B+128%

Neurogene$690.7M+123%

Tenaya Therapeutics, Inc.$167.0M+31.6%

PepGen$131.4M+181%

Metagenomi Therapeutics, Inc. $45.6M-51.5%

PAS

Passage Bio, Inc.$14.8M-32.5%

By revenue growth

GeneDx Holdings+34.1%

Ultragenyx Pharmaceutical+13.5%

Taysha Gene Therapies, Inc.+3.4%

By net margin

GeneDx Holdings-17.58%+1.9pp

Ultragenyx Pharmaceutical-90.92%+2.2pp

Taysha Gene Therapies, Inc.-1,738.4%-537pp

Profile

Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for rare and devastating neurological diseases. The company utilizes its proprietary EXACT technology to engineer transgene regulation, aiming to address complex monogenic disorders that are not treatable by conventional gene therapy. Their primary mission is to deliver therapeutic levels of genetic material to the central nervous system through advanced adeno-associated virus delivery systems.

Competitive position

Neurogene is a clinical-stage innovator utilizing a proprietary transgene regulation platform (EXACT) and internal cGMP manufacturing to differentiate itself from conventional gene therapy competitors.

GeographiesUnited States, United Kingdom

Customer segmentsRare disease patients, Neurology specialists

Business modelR&D intensive biopharmaceutical, Clinical-stage drug development

SuppliersViral vector components, Laboratory equipment, Academic research collaborations, Clinical trial sites

CustomersSpecialty pharmacies, Hospitals, Neurological treatment centers

CountryUnited States of America

Listed2023

Employees91.0

CEORachel L. McMinn

SectorHealthcare

IndustryBiotechnology

Websiteneurogene.com

FilingsSEC EDGAR

Questions, answered.

What is Neurogene's market cap?: Neurogene (NGNE) has a market capitalization of $690.7M and trades on NASDAQ.
Who are Neurogene's competitors?: Neurogene's key competitors include Ultragenyx Pharmaceutical, Passage Bio, Inc. Common Stock, Taysha Gene Therapies, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Neurogene partner with?: Neurogene's notable partners include University of Edinburgh.
Where is Neurogene headquartered?: Neurogene is headquartered in United States of America and employs approximately 91 people. It has been publicly traded since 2023.